Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Cohen & Steers, Inc. (CNS)
NYSEFinancialsAsset ManagementSnapshot 2026-11-04
$73.23-3.28%
Close 2026-11-05 · 1-day change
NYSEFinancialsAsset ManagementSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
3.95 → 3.54 EPS · FY ending Dec 31, 2027 · 2 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 2 to 2; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for CNS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Dividend per share grows to at least $0.67 by 2026-Q1 | Dividends grew from $0.59 to $0.67 per share. | Intact | Dividend per share falls below $0.59 in 2026-Q1 | Dividend per share: $0.67 per share FY2026-Q3; GAAP. Published target: >= $0.67 per share. The stored target says 2026-Q1; this source reports FY2026-Q3. Fiscal/calendar alignment needs review. Oct 30, 20260.67 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
CNS is a financials business with a durable-premium valuation profile, but the evidence does not establish strong execution across its stated growth priorities. The thesis is currently intact, while recent momentum has weakened and earnings quality remains fragile.
CNS is valued at a 1.62 premium versus peers, and the expectations gap is elevated. The snapshot labels the priced-in setup unjustified, citing expensive valuation and weak execution quality, so the premium appears to assume more durability than the evidence clearly supports.
Near term, financial performance is neutral, with earnings beats reported in July and October, but company momentum fell from 1.6 to -16.8. Management has named priorities in real assets, wealth, and private markets, yet the supplied evidence gives little channel-specific proof of progress; recent revenue increased between the reported first and third quarters. The next guidance update and the CFO transition are relevant execution checks.
The main downside scenario is a guidance cut, which could signal weaker estimates and add pressure to a thesis already marked by fragile earnings quality. Rate cuts could also weigh on the financials sector, while continued earnings strength and higher guidance from sector bellwethers such as BLK, BX, and KKR would support sector momentum. Over the multi-year view, clearer evidence that management’s stated priorities are producing results would help justify the valuation premium.
For the next one to three years, CNS has an intact but fragile thesis: recent earnings beats are constructive, while weaker momentum, limited evidence of priority delivery, and an expensive valuation are important constraints. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in Cohen & Steers, Inc.'s published investment case. The stated target is >= $50.1 million. |
| Intact |
| Operating income falls below $43M in 2026-Q1 |
Operating income: $51.065M FY2026-Q3; GAAP. Published target: >= $50.1 million. The stored target says 2026-Q1; this source reports FY2026-Q3. Fiscal/calendar alignment needs review. Oct 30, 202651,065,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue grows to at least $146M by 2026-Q1 | A primary condition in Cohen & Steers, Inc.'s published investment case. The stated target is >= $145.6 million. | Intact | Revenue falls below $133M in 2026-Q1 | Revenue: $157.427M FY2026-Q3; GAAP. Published target: >= $145.6 million. The stored target says 2026-Q1; this source reports FY2026-Q3. Fiscal/calendar alignment needs review. Oct 30, 2026157,427,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$3.87 → $3.54 · observed estimates
$0.67B → $0.62B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $3.87 | $665,522,100 | 3 / 2 |
| 2026-07-25 | $3.87 | $665,522,100 | 3 / 2 |
| 2026-07-26 | $3.87 | $665,522,100 | 3 / 2 |
| 2026-07-27 | $3.87 | $665,522,100 | 3 / 2 |
| 2026-07-28 | $3.87 | $665,522,100 | 3 / 2 |
| 2026-07-29 | $3.87 | $687,611,209 | 2 / 1 |
| 2026-07-30 | $3.89 | $666,664,560 | 3 / 2 |
| 2026-07-31 | $3.89 | $666,664,560 | 3 / 2 |
| 2026-08-01 | $3.89 | $689,896,105 | 2 / 1 |
| 2026-08-02 | $3.89 | $666,664,560 | 3 / 2 |
| 2026-08-03 | $3.89 | $666,664,560 | 3 / 2 |
| 2026-08-04 | $3.89 | $689,896,105 | 2 / 1 |
| 2026-08-05 | $3.89 | $689,896,105 | 2 / 1 |
| 2026-08-06 | $3.89 | $689,896,105 | 2 / 1 |
| 2026-08-07 | $3.89 | $689,896,105 | 2 / 1 |
| 2026-08-08 | $3.89 | $689,896,105 | 2 / 1 |
| 2026-08-09 | $3.89 | $666,664,560 | 3 / 2 |
| 2026-08-10 | $3.89 | $689,896,105 | 2 / 1 |
| 2026-08-11 | $3.89 | $666,664,560 | 3 / 2 |
| 2026-08-12 | $3.89 | $689,896,105 | 2 / 1 |
| 2026-08-13 | $3.89 | $689,896,105 | 2 / 1 |
| 2026-08-14 | $3.89 | $689,896,105 | 2 / 1 |
| 2026-08-15 | $3.89 | $689,896,105 | 2 / 1 |
| 2026-08-16 | $3.89 | $689,896,105 | 2 / 1 |
| 2026-08-17 | $3.89 | $689,896,105 | 2 / 1 |
| 2026-08-18 | $3.89 | $689,896,105 | 2 / 1 |
| 2026-08-19 | $3.89 | $689,896,105 | 2 / 1 |
| 2026-08-20 | $3.94 | $689,896,105 | 2 / 1 |
| 2026-08-21 | $3.94 | $689,896,105 | 2 / 1 |
| 2026-08-22 | $3.94 | $689,896,105 | 2 / 1 |
| 2026-08-23 | $3.94 | $689,896,105 | 2 / 1 |
| 2026-08-24 | $3.94 | $689,896,105 | 2 / 1 |
| 2026-08-25 | $3.94 | $689,896,105 | 2 / 1 |
| 2026-08-26 | $3.94 | $689,896,105 | 2 / 1 |
| 2026-08-27 | $3.94 | $689,896,105 | 2 / 1 |
| 2026-08-28 | $3.94 | $689,896,105 | 2 / 1 |
| 2026-08-29 | $3.94 | $689,896,105 | 2 / 1 |
| 2026-08-30 | $3.94 | $689,896,105 | 2 / 1 |
| 2026-08-31 | $3.94 | $689,896,105 | 2 / 1 |
| 2026-09-01 | $3.94 | $689,896,105 | 2 / 1 |
| 2026-09-02 | $3.94 | $689,896,105 | 2 / 1 |
| 2026-09-03 | $3.94 | $689,896,105 | 2 / 1 |
| 2026-09-04 | $3.94 | $689,896,105 | 2 / 1 |
| 2026-09-05 | $3.94 | $689,896,105 | 2 / 1 |
| 2026-09-06 | $3.94 | $689,896,105 | 2 / 1 |
| 2026-09-07 | $3.94 | $689,896,105 | 2 / 1 |
| 2026-09-08 | $3.94 | $689,896,105 | 2 / 1 |
| 2026-09-09 | $3.94 | $689,896,105 | 2 / 1 |
| 2026-09-10 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-09-11 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-09-12 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-09-13 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-09-14 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-09-15 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-09-16 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-09-17 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-09-18 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-09-19 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-09-20 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-09-21 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-09-22 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-09-23 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-09-24 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-09-25 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-09-26 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-09-27 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-09-28 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-09-29 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-09-30 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-10-01 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-10-02 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-10-03 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-10-04 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-10-05 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-10-06 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-10-07 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-10-08 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-10-09 | $3.95 | $689,896,105 | 2 / 1 |
| 2026-10-10 | $3.81 | $689,896,105 | 2 / 1 |
| 2026-10-11 | $3.81 | $689,896,105 | 2 / 1 |
| 2026-10-12 | $3.81 | $689,896,105 | 2 / 1 |
| 2026-10-13 | $3.81 | $689,896,105 | 2 / 1 |
| 2026-10-14 | $3.81 | $689,896,105 | 2 / 1 |
| 2026-10-15 | $3.60 | $628,527,631 | 2 / 1 |
| 2026-10-16 | $3.60 | $628,527,631 | 2 / 1 |
| 2026-10-17 | $3.60 | $628,527,631 | 2 / 1 |
| 2026-10-18 | $3.58 | $628,527,631 | 2 / 1 |
| 2026-10-19 | $3.58 | $628,527,631 | 2 / 1 |
| 2026-10-20 | $3.58 | $628,527,631 | 2 / 1 |
| 2026-10-21 | $3.58 | $628,527,631 | 2 / 1 |
| 2026-10-22 | $3.58 | $628,527,631 | 2 / 1 |
| 2026-10-23 | $3.58 | $628,527,631 | 2 / 1 |
| 2026-10-24 | $3.58 | $628,527,631 | 2 / 1 |
| 2026-10-25 | $3.58 | $628,527,631 | 2 / 1 |
| 2026-10-26 | $3.58 | $628,527,631 | 2 / 1 |
| 2026-10-27 | $3.58 | $628,527,631 | 2 / 1 |
| 2026-10-28 | $3.58 | $628,527,631 | 2 / 1 |
| 2026-10-29 | $3.58 | $628,527,631 | 2 / 1 |
| 2026-10-30 | $3.58 | $628,527,631 | 2 / 1 |
| 2026-10-31 | $3.58 | $628,527,631 | 2 / 1 |
| 2026-11-01 | $3.58 | $628,527,631 | 2 / 1 |
| 2026-11-02 | $3.58 | $628,527,631 | 2 / 1 |
| 2026-11-03 | $3.58 | $628,527,631 | 2 / 1 |
| 2026-11-04 | $3.54 | $624,998,104 | 2 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 1 Hold · 1 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.